Compare Global X Cybersecurity (BUG) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X Cybersecurity vs TG Therapeutics Inc — how do they compare? Global X Cybersecurity trades at $42.92, while TG Therapeutics Inc trades at $49.94 (market cap $7.53B). The key difference: Global X Cybersecurity is trading nearer its 52-week high, TG Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| BUG | TGTX | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $43.00 | $59.06 |
52-Week Low | $23.30 | $26.94 |
Market Cap | — | $7.53B |
Enterprise Value | — | $7.73B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BUG, the Global X Cybersecurity ETF, trades at $41.68, up 2.36% today and near its 52-week high, with a strong bullish technical signal from moving averages. The ETF has gained significant momentum, rising 82.25% from its 52-week low, as cybersecurity spending forecasts exceed $300 billion in 2026. Recent news highlights sector resilience against AI threats, though key financial ratios like P/E and P/S are not provided in the available data.
The outlook for BUG is positive, driven by robust cybersecurity demand and AI-related security needs, but risks include premium valuations, concentrated US SMID-cap exposure, and potential sector volatility. Analyst sentiment remains bullish with reiterated buy ratings, yet investors should note overbought short-term signals and competitive pressures in the evolving tech landscape.
TG Therapeutics (TGTX) trades at $49.76, up 0.42% in the last session, with a bearish technical signal from moving averages. Recent earnings missed estimates, but revenue growth is strong, driven by BRIUMVI sales, with 2026 guidance raised to $950 million. The stock faces near-term pressure from earnings underperformance and a legal investigation into potential fiduciary breaches.
The outlook is mixed: strong revenue momentum and a high analyst buy rating (84.62%) support upside to the $63.75 consensus target, but risks include earnings volatility, high valuation multiples, and legal overhangs. Investors should weigh robust growth prospects against execution and sentiment challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Global X Cybersecurity
BUG is a thematic ETF that invests in companies at the forefront of the global cybersecurity industry. It provides concentrated exposure to leaders in network security, endpoint protection, and cloud security, such as Fortinet, Akamai, and CrowdStrike.
Read more on BUG →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
